Evidence map›Paper›PMID 41284265›Full record

ArticleJournal of the American Chemical Society2025

Montserrat Escobar-Rosales, Cristina Montaner, Marc Expòsit, Roberta Lucchi, Cristina Díaz-Perlas, David Baker, Benjamí Oller-Salvia

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Montserrat Escobar-RosalesInstitut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, Barcelona 08017, Spain.ORCID 0000-0001-9982-7750
Cristina MontanerInstitut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, Barcelona 08017, Spain.ORCID 0009-0005-1624-6034
Marc ExpòsitDepartment of Biochemistry, University of Washington, Seattle, Washington 98195, United States.
Roberta LucchiInstitut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, Barcelona 08017, Spain.
Cristina Díaz-PerlasInstitut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, Barcelona 08017, Spain.ORCID 0000-0002-9552-3896
David BakerDepartment of Biochemistry, University of Washington, Seattle, Washington 98195, United States.
Benjamí Oller-SalviaInstitut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, Barcelona 08017, Spain.ORCID 0000-0002-8140-6111

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widespread expression of therapeutic targets in both diseased and healthy tissues poses a major challenge for protein-based therapeutics, often leading to dose-limiting side effects. One promising strategy to enhance selectivity is reversible inactivation via affinity masks tethered through cleavable linkers responsive to disease-specific cues. Here, we introduce a workflow for the

Indexed as

PeptidesErbB ReceptorsHumansProtein BindingErbB ReceptorsPeptides

Identifiers

PMID41284265
PMCPMC12703739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.